NVIDIA's AI startup ecosystem is driving innovation in European healthcare, from creating large-scale biodiversity databases to deploying AI factories for rare disease research.
AI-Powered Healthcare Solutions
At NVIDIA GTC Paris, European healthcare and life sciences companies showcased their leadership in global medical innovation. These firms leverage AI to address challenges like staff shortages, aging populations, and rising costs across biopharma, healthcare management, and digital health. Supported by NVIDIA's startup accelerator program, they gain access to advanced development tools, technical training, and connections to venture capital.
Using platforms like NVIDIA BioNeMo, NVIDIA DGX Cloud, and NVIDIA's cloud partner network, European companies are advancing drug development, patient care, and regional healthcare systems.
Basecamp Research's Genomic Database
London-based startup Basecamp Research developed BaseData, the world's largest and most diverse generative AI biological dataset for life sciences. Built from samples across 26 countries and over 125 locations, it includes over 9.8 billion new biological sequences and more than 1 million previously unknown species. Compared to the public UniRef 50 database, BaseData updates 30 times faster and grows up to 1,000 times quicker.
The dataset trains next-generation foundation models on NVIDIA DGX Cloud Lepton using the NVIDIA BioNeMo framework. By overcoming challenges in data scale, diversity, and governance, Basecamp's approach integrates new data supply chains, global partnerships, and GPU-accelerated workflows to train advanced biological models, accelerating drug discovery.
Phil Lorenz, Basecamp's CTO, stated, "Optimizing data scale is key to breaking current biological model limitations. With NVIDIA's compute and AI stack, we're training models that understand and generate biological data in unprecedented ways."
AI Agents Transform UK Healthcare
The UK's Guy's and St. Thomas' NHS Foundation Trust, serving over 2.8 million people annually, collaborates with General Catalyst, Hippocratic AI, and Sword Health on the PATH initiative. This program integrates advanced AI agents to streamline specialist wait times, optimize pain management, and simplify triage processes.
Hippocratic AI's conversational agents automate patient communication, medical history collection, and referral verification. Sword Health's AI care platform supports over 500,000 patients globally in areas like physical pain and pelvic health, completing 6.5 million AI care sessions. The initiative also addresses the UK's elective care crisis, with over 53,000 patients awaiting initial appointments at Guy's and St. Thomas' alone, by prioritizing cases based on clinical need.
Ian Abbs, CEO of Guy's and St. Thomas', said, "PATH aims to deliver better, faster, and fairer healthcare by combining AI with clinical care to create a more proactive NHS."
Pangaea Data Bridges Rare Disease Gaps
Pangaea Data, based in London and San Francisco, uses its AI platform to identify untreated or undertreated patients from medical records, addressing gaps in rare and complex disease care. Powered by NVIDIA NeMo Agent toolkit and NVIDIA NIM microservices, the platform simulates clinical record reviews to calculate scores for diseases with nonspecific symptoms like fever, nausea, and headaches.
Vibhor Gupta, Pangaea's founder and CEO, noted, "NeMo Agent and NVIDIA NIM reduced our platform's disease configuration time from weeks to a day, accelerating our mission to improve global patient outcomes."
Deployed in healthcare systems across the US, UK, Spain, and Barbados, Pangaea's platform supports pharmaceutical suppliers, health systems, and policymakers in optimizing care delivery and health equity.
NVIDIA DGX Cloud Empowers Startups
European venture capital firms like Sofinnova leverage NVIDIA DGX Cloud Lepton to support AI startups. Selected firms provide portfolio companies with early access to 25 NVIDIA GPU nodes for three months, along with dedicated technical support, enabling expansion into markets requiring localized computing.
Startups like Paris-based Cure51, UK-based Sensible Biotechnologies, and Molecular Glue Labs benefit from DGX Cloud. Cure51 achieved 17x faster genomic analysis and 50% cost reduction using NVIDIA BioNeMo. Sensible shortened mRNA therapy design cycles from 15 days to one, while Molecular Glue Labs validated new protein engineering methods.
